Reaction
Immune-Mediated Encephalitis reporting signals
As of the last recalculation, Immune-Mediated Encephalitis appears in 489 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 139.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 203 | 139.7 | 140.0 |
| Ipilimumab | 103 | 128.4 | 128.7 |
| Nivolumab | 164 | 108.1 | 108.3 |
| Lenvatinib | 52 | 75.4 | 75.5 |
| Atezolizumab | 56 | 69.2 | 69.3 |
| Durvalumab | 21 | 45.9 | 45.9 |
| Paclitaxel (Aibumin-Bound) | 52 | 30.0 | 30.0 |
| Carboplatin | 70 | 27.2 | 27.2 |
| Paclitaxel | 53 | 25.4 | 25.4 |
| Pemetrexed | 12 | 24.4 | 24.4 |
| Pemetrexed Disodium | 17 | 19.6 | 19.6 |
| Axitinib | 6 | 13.3 | 13.3 |
| Cabozantinib | 13 | 11.8 | 11.8 |